🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06608407
Enrolling by invitation Not applicable

Platelet Rich Plasma in the Prevention of Adhesion Reformation

NCT06608407 · tracked via the Priya Life Science China tracker
Sponsor
Fu Xing Hospital, Capital Medical University
Phase
Not applicable
Started
2023-10-10
Last updated
2025-03-11

Condition(s) studied

Intrauterine AdhesionAsherman Syndrome

Investigational drug(s) / intervention(s)

PRP group

PRP group: After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.

Study summary

Asherman syndrome, which occurs after trauma to the basalis layer of the endometrium. It seems that the role of postoperative platelet rich plasma(PRP)therapy in the prevention of recurrence of IUA is still controversial. To investigate if PRP therapy can prevent adhesion reformation after adhesiolysis.

After the completion of hysteroscopic adhesiolysis, recruited patients will be randomized to one of the two treatment groups by computer-generated numbers: having PRP after hysteroscopic adhesiolysis; and the control group without PRP treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: Clinical diagnosis of Asherman's syndrome. AFS score \>7. Exclusion Criteria: 1. Leiomyoma; 2. Endometrial polyps; 3. Ppolycystic ovarian syndrome (PCOS).

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Fu Xing Hospital, Capital Medical University Beijing Beijing Municipality
Fuxing hospital Beijing Beijing Municipality

More Fu Xing Hospital, Capital Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06608407 on ClinicalTrials.gov ↗ ← All trials in China